These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
29. The safety of triptans in the treatment of patients with migraine. Jamieson DG Am J Med; 2002 Feb; 112(2):135-40. PubMed ID: 11835952 [TBL] [Abstract][Full Text] [Related]
30. Mechanism of migraine and action of antimigraine medications. Spierings EL Med Clin North Am; 2001 Jul; 85(4):943-58, vi-vii. PubMed ID: 11480266 [TBL] [Abstract][Full Text] [Related]
31. Neurogenic inflammation in the context of migraine. Williamson DJ; Hargreaves RJ Microsc Res Tech; 2001 May; 53(3):167-78. PubMed ID: 11301492 [TBL] [Abstract][Full Text] [Related]
32. The pathophysiology of migraine: year 2005. Buzzi MG; Moskowitz MA J Headache Pain; 2005 Jun; 6(3):105-11. PubMed ID: 16355290 [TBL] [Abstract][Full Text] [Related]
33. Substance P receptor antagonists in the therapy of migraine. May A; Goadsby PJ Expert Opin Investig Drugs; 2001 Apr; 10(4):673-8. PubMed ID: 11281817 [TBL] [Abstract][Full Text] [Related]
34. Can we develop neurally acting drugs for the treatment of migraine? Goadsby PJ Nat Rev Drug Discov; 2005 Sep; 4(9):741-50. PubMed ID: 16121129 [TBL] [Abstract][Full Text] [Related]
35. New insights into the molecular actions of serotonergic antimigraine drugs. Durham PL; Russo AF Pharmacol Ther; 2002; 94(1-2):77-92. PubMed ID: 12191595 [TBL] [Abstract][Full Text] [Related]
36. 5-Hydroxytryptamine and the pathophysiology of migraine. Humphrey PP J Neurol; 1991; 238 Suppl 1():S38-44. PubMed ID: 2045830 [TBL] [Abstract][Full Text] [Related]
37. [Treatment of migraine]. Hoffmann J; Reuter U Dtsch Med Wochenschr; 2007 Oct; 132(41):2153-8. PubMed ID: 17924297 [TBL] [Abstract][Full Text] [Related]
38. The pharmacology of current anti-migraine drugs. Peroutka SJ Headache; 1990 Jan; 30(1 Suppl):5-11; discussion 24-8. PubMed ID: 1969855 [TBL] [Abstract][Full Text] [Related]